FibroBiologics Inc
FBLG
Company Profile
Business description
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
Contact
455 East Medical Center Boulevard
Suite 300
HoustonTX77598
USAT: +1 281 671-5150
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
15
Stocks News & Analysis
stocks
Chart of the Week: CGT reform strengthens the case for dividend investing
Why dividend stocks are gaining an edge after tax reform.
stocks
Finding ASX opportunities in lofty market conditions
A widening valuation gap is revealing more discounted ASX shares with moats.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,122.70 | 62.80 | -0.68% |
| CAC 40 | 8,475.70 | 67.43 | 0.80% |
| DAX 40 | 25,450.50 | 9.98 | -0.04% |
| Dow JONES (US) | 51,594.14 | 1,153.18 | -2.19% |
| FTSE 100 | 10,910.60 | 2.19 | 0.02% |
| HKSE | 25,858.88 | 50.96 | 0.20% |
| NASDAQ | 24,442.94 | 433.97 | -1.74% |
| Nikkei 225 | 61,867.43 | 433.24 | 0.71% |
| NZX 50 Index | 13,762.78 | 213.89 | -1.53% |
| S&P 500 | 7,316.15 | 112.63 | -1.52% |
| S&P/ASX 200 | 8,967.70 | 57.10 | -0.63% |
| SSE Composite Index | 3,804.69 | 23.78 | -0.62% |